1. United States Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Danaher Corporation

Danaher Corporation

208.80
EUR
+0.90
(+0.43%)
4.91EPS
33.70P/E
117.28BMarket Cap
Feb 03Next Earn
Danaher Corporation
XETR:DAP
(Deutsche Borse Xetra)

Recent

price

208.80

P/E

ratio

33.70

div

yld

0.57%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
USD
19.21
23.8
26.33
26.27
18.32
20.68
24.42
22.3
24.33
25.05
31.55
34.71
36.74
32.44
32.66
34.47
35.47
Revenue per Share
2.74
3.21
3.45
3.87
3.7
4.81
3.69
3.58
3.78
4.11
4.97
8.77
9.8
6.44
5.33
5.07
5.66
Basic EPS, GAAP
2.9
3.39
4.26
4.38
4.69
4.71
4.24
4.18
4.91
4.64
7.67
9.96
10.21
7.85
7.24
7.38
7.72
Free Cash Flow per Basic Share
0.08
0.09
0.12
0.07
0.32
0.51
1.28
0.54
0.62
1.05
0.87
1.04
1.13
1.69
1.05
1.23
1.36
Dividend per Share
20.89
24.58
27.66
32.07
33.19
34.49
33.23
37.84
40.22
41.22
51.33
58.6
66.48
72.36
68.9
74.32
74.81
Book Value per Share
-0.57
-4.96
-4.06
0.14
0.92
-11.46
-18.26
-15
-6.63
-5.45
-28.42
-30.95
-11.92
-12
-13.24
-11.93
-23.03
Tangible Book Value per Share
653
676
693
696
702
698
691
696
701
715
706
715
725
737
731
713
708
Basic Weighted Avg Shares
12,550
16,091
18,260
18,283
12,867
14,434
16,882
15,519
17,049
17,911
22,284
24,802
26,643
23,890
23,875
24,568
25,107
Sales/Revenue/Turnover
16.15
15.85
16.95
17.07
15.89
14.98
16.2
16.58
17.92
18.25
18.99
25.75
28.29
21.77
20.37
19.09
20.42
Operating Margin (%)
388
635
840
851
718
881
1,128
1,117
1,178
1,189
1,775
2,062
2,132
2,166
2,352
2,447
2,531
Depreciation Expense
1,793
2,172
2,392
2,695
2,598
3,357
2,554
2,492
2,651
3,008
3,646
6,433
7,209
4,764
3,899
3,614
4,004
Net Income, GAAP
22.94
20.94
23.63
24.17
21.45
14.35
17.54
14.59
18.77
26.41
18.89
16.34
11.45
16.32
16.08
14.95
16.21
Effective Tax Rate (%)
14.29
13.5
13.1
14.74
20.19
23.26
15.13
16.06
15.55
16.79
16.36
25.94
27.06
19.94
16.33
14.71
15.95
Profit Margin (%)
2,425
2,100
3,382
4,586
4,035
1,666
-209
2,058
2,252
20,664
6,400
3,508
7,494
5,663
2,699
5,949
5,276
Working Capital
2,784
5,207
5,288
3,437
3,402
12,025
9,674
10,327
9,689
22,156
21,978
23,057
19,858
17,661
16,468
19,495
25,147
LT Debt
13,773
16,972
19,084
22,451
23,450
23,764
23,077
26,368
28,227
30,282
39,777
45,177
50,090
53,490
49,550
52,541
52,592
Total Equity
10.14
10.61
10.31
9.36
6.01
5.76
6.23
6.04
6.59
5.27
5.95
8.12
9.52
6.02
5.8
5.71
5.78
Return on Invested Capital (%)
12.09
11.75
10.76
11.12
10.11
10.94
7.52
7.23
7.38
6.8
6.74
10.16
10.62
6.96
5.92
5.53
5.71
Return on Capital (%)
14.15
14.19
13.32
13.02
11.36
14.27
10.94
10.1
9.72
10.34
10.77
15.99
15.73
9.31
7.57
7.08
7.63
Return on Common Equity (%)

Capital Structure

USD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
201
923
1,411
LT Borrowings
18,416
17,561
25,147
LT Finance Leases
1,079
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
707
708
703
Market Capitalization
162,643
133,327
133,987

Working Capital

USD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
12,756
13,935
13,381
Cash, Cash Equivalents & STI
4,615
5,701
4,348
Accounts Receivable, Net
3,913
3,819
3,965
Inventories
2,489
2,608
3,260
Total Current Liabilities
6,807
7,460
8,105
Payables & Accruals
2,451
6,537
6,694
ST Debt
201
923
1,411
Deferred Revenue
1,353
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
8.7%
5.98%
6.04%
Free Cash Flow
7.08%
0.88%
-0.68%
Net Income, GAAP
4.38%
5.82%
-7.31%
Sales/Revenue/Turnover
5.95%
2.25%
2.9%
Total Cash Common Dividend
22.81%
18.62%
14.32%

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
5,796
5,743
5,798
6,538
23,875
2025
5,741
5,936
6,053
6,838
24,568
2026
5,951
6,265
- -
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.47
1.23
1.13
1.5
5.33
2025
1.33
0.77
1.28
1.69
5.07
2026
1.45
1.23
- -
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.24
0.27
0.27
0.27
1.05
2025
0.27
0.32
0.32
0.32
1.23
2026
0.32
0.4
- -
- -
- -
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Danaher Corporation (NYSE: DHR), founded in 1984 and headquartered in Washington, D.C., operates as a leading global science and technology innovator focused on life sciences and diagnostics. The company conducts business through three primary segments: biotechnology, which develops products and services for therapeutic development including bioprocessing solutions, plasmid DNA, mRNA, proteins, and genomic medicines via brands such as Cytiva, Aldevron, and Abcam; life sciences, offering instruments like mass spectrometers, flow cytometry systems, microscopes, genomics consumables, lab automation, centrifugation, particle characterization, and gene and cell therapy tools; and diagnostics, providing clinical instruments, reagents, consumables, software, and services for disease diagnosis in hospitals, physicians' offices, reference laboratories, and critical care settings through subsidiaries including Cepheid and Beckman Coulter. Danaher serves customers worldwide across biopharmaceutical, research, healthcare, and precision medicine markets, employing approximately 63,000 associates in over 125 countries. Recent developments include the 2023 acquisition of Abcam for proteomic research consumables to accelerate drug discovery; a January 2025 investment partnership with Innovaccer Inc. through Danaher Diagnostics LLC and Danaher Ventures LLC to advance AI-enabled diagnostics and precision medicine; and a May 2025 diagnostic development and commercialization alliance with AstraZeneca to scale next-generation AI-powered diagnostics solutions.

Company News

Company News APIChatGPT

  • seekingalpha.com

    Danaher Q3 Recap: Decent Results, Still A Hold

  • fool.com

    Why Danaher Stock Bounced Higher Today

  • seekingalpha.com

    Danaher Corporation (DHR) Q3 2026 Earnings Call Transcript

  • fool.com

    Danaher: 3 Key Takeaways for Long-Term Investors

  • gurufocus.com

    Danaher Corp (DHR) (Q3 2026) Earnings Call Highlights: Core Growth Accelerates to 5.5% Ex-Respiratory as EPS Guidance Rises

  • seekingalpha.com

    Danaher Q3 Review: Interested To See What The New Management Will Bring

  • zacks.com

    DHR Q3 Earnings Beat on Biotechnology Strength, Sales in Line

  • benzinga.com

    Danaher Beats Profit Estimates, Raises Outlook as Customer Demand Improves

  • marketbeat.com

    Danaher Q3 Earnings Call Highlights

  • zacks.com

    Danaher (DHR) Reports Q3 Earnings: What Key Metrics Have to Say

  • zacks.com

    Danaher (DHR) Tops Q3 Earnings and Revenue Estimates

  • prnewswire.com

    Danaher Reports Third Quarter 2026 Results

  • defenseworld.net

    Danaher Corporation $DHR Stock Holdings Lowered by Louisbourg Investments Inc.

  • benzinga.com

    Danaher Likely To Report Higher Q3 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

  • defenseworld.net

    Danaher Corporation $DHR Stock Bought by SteelPeak Wealth LLC

  • defenseworld.net

    Danaher Corporation $DHR Stock: IFP Advisors Inc Increases Stake

  • defenseworld.net

    Danaher Corporation $DHR Shares Bought by Birch Hill Investment Advisors LLC

  • defenseworld.net

    2,506 Danaher Corporation $DHR Shares Acquired by Forbes J M & Co. LLP

  • defenseworld.net

    15,838 Shares of Danaher Corporation $DHR Acquired by CWS Financial Advisors LLC

  • defenseworld.net

    76,426 Shares in Danaher Corporation $DHR Bought by Aull & Monroe Investment Management Corp